Roche's Alecensa latest beneficiary of faster China drug approvals [Reuters]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Reuters
Roche's Alecensa latest beneficiary of faster China drug approvals | Reuters Reuters Staff 1 Min Read ZURICH (Reuters) - Chinese regulators are speeding up drug approvals, with Roche’s Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies’ growth plans. China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals. Reporting by John Miller All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. Roche's Alecensa latest beneficiary of faster China drug approvals ZURICH (Reuters) - Chinese regulators are speeding up drug approvals, with Roche’s Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmace
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Do you have seasonal allergies? Here's how to find out and what to do [CNN]CNN
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-US FDA grants full approval to AbbVie's ovarian cancer therapy [Yahoo! Finance]Yahoo! Finance
- Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer [Yahoo! Finance]Yahoo! Finance
- Lonza to buy U.S. biologics site from Roche for $1.2B [Seeking Alpha]Seeking Alpha